During a 3-year period at our hospital, 54 consecutively observed patients with parametric, locally advanced, metastatic gastric carcinoma were treated with fluorouracil + adriaiiiycin + mitomycin C. Of 47 evaluable patients, 44.6% had an objective response (complete + partial response) and 29.7% had stabilized disease. The median duration of response was 7.5 months. The median survival was 8.9 months for all patients. In particular, the survival of responders (>12 months) and of patients with stabilized disease (8.6 months) was significantly longer than that of patients with progressive disease (4.5 months). Toxicity was limited and reversible, which allowed treatment also of patients in poor general condition (PS 3–4 of the Zubrod scale).
Get full access to this article
View all access options for this article.
References
1.
BerettaG., FraschiniP., LabiancaR., TedeschiL., LuporiniG.: Chemotherapy of gastric carcinoma with FAM combination. In: Diagnosis and Treatment of Upper Gastrointestinal Tumors.FriedmanM., OgawaM., KisnerD., Eds., pp. 381–388, Excerpta Medica, Int. Congress Series 542, Amsterdam, Oxford, Princeton, 1981.
2.
BernathA.M., ThornsvardC.T.: Treatment of advanced gastric carcinoma with BCNU, adriamycin, 5-FU and mitomycin C (BAFMi).Proc. AACR/ASCO, 20, C87, 1979.
3.
BitranJ.D., DesserR.K., KozloffM.F., BillingsA.A., ShapiroC.M.: Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin and mitomycin C (FAM).Cancer Treat. Rep., 63: 20494052, 1979.
4.
CavalliF.: New drugs in the treatment of gastric cancer: Methodological problems and some data. In: Diagnosis and Treatment of Upper Gastrointestinal Tumors.FriedmanM., OgawaM., KisnerD., Eds., pp. 412–417, Excerpta Medica, Int. Congress. Series 542, Amsterdam, Oxford, Princeton, 1981.
5.
D'AntonaA., FraschiniP., LabiancaR., BerettaG.: Trattamento del carcinoma gastrico in fase avanzata con l'associazione 5-FU + BCNU. In: Riunioni Integrate di Oncologia, Firenze, 15–16 Giugno 1978, Abstr. 117.
6.
FraschiniP., BerettaG., TedeschiL., FormentiS., ArnoldiE., LuporiniG.: Polichemioterapia FAM nel carcinoma dello stomaco in fase avanzata (Abstr.).Tumori, 67: 86, 1981.
KovachJ.S., MoertelC.C., SchuttA.J.: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.Cancer, 33: 563–568, 1974.
9.
LaurenP.: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma.An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand., 64: 31–49, 1965.
10.
LeviJ.A.: Australian studies in early and advanced stage gastric cancer. In: Diagnosis and Treatment of Upper Gastrointestinal Tumors. M. Friedman, OgawaM., KisnerD. Esd., pp. 370–379, Excerpta Medica, Int. Congress Series 542, Amsterdam, Oxford, Princeton, 1981.
LuporiniG., FraschiniP., BerettaG., LabiancaR., FormentiS.: Combination chemotherapy with fluorouracil+doxorubicin+mitomycin C (FAM) in advanced/metastatic carcinoma of the stomach. UICC Conf. Clin.Oncology, Lausanne, 110(Abst. 12–0382), 1981.
13.
MacDonaldJ., ScheinP., UenoW., WoolleyP.: 5-Fluorouracil (5 + FU), mitomycin C (MMC) and adriamycin (ADR) - FAM: A new combination chemotherapy program for advanced gastric carcinoma.Proc. AACR/ASCO, 17: 264, 1976.
14.
MacDonaldJ.S., ScheinP.S., WoolleyP.V., BoironM., GisselbrechtC., BrunetR., LagardeC.: 5-Fluorouracil (5-FU), mitomycin C (MMC) and adriamycin (ADR) FAM combination chemotherapy results in 61 patients with advanced gastric cancer.Proc. AACR/ASCO, 20, Abst. C-434, 1979.
15.
MacDonaldJ.S., WoolleyP.V., SmytheT., UenoW., HothD., ScheinP.S.: 5-Fluorouracil, adriamycin and mitomycin C (FAM) combination chemotherapy in the treatment of advanced cancer.Cancer, 44: 42–47, 1979.
16.
MakuchR.W.: Statistical guidelines for medical research reports.Cancer Treat. Rep., 66: 217–219, 1982.
17.
MillerA.B., HoogstraatenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
18.
MontinariF., LuporiniG.: Recent patterns of advanced phase carcinomas of the gastroenteric tract and of the lung. In: Interdisciplinary Trends in Surgery, Vol. I, pp. 497–505. MontorsiW., DonatiL., LongoT., Eds., Minerva Medica, Torino, 1979.
19.
PanettiereF., HeilbrunL.: Comparison of two different combinations of adriamycin, mitomycin C and 5-FU in the management of gastric carcinoma. A SWOG study. Proc. AACR/ASCO, 20, Abs. C-102, 1979.
20.
The Gastrointestinal Tumor Study Group.Phase II-III Chemotherapy Studies in Advanced Gastric Cancer.Cancer Treat. Rep., 63: 1871–1876, 1979.
21.
ZubrodC.G., SchneidermanM.A., FreiE. I.I.I.,: Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylenethiophospharamide.J. Chronic. Dis., 11: 7–13, 1960.
22.
WoolleyP., MacDonaldJ.S., SmytheT., HallerD., HothD., RosenoffS., ScheinP.: A phase II trial of Ftorafur, adriamycin and mitomycin C (FAM II) in advanced gastric adenocarcinoma.Cancer, 44: 1211–1214, 1979.
